Revance

Revance Therapeutics is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator, Daxxify (DaxibotulinumtoxinA-lanm). Daxxify is the first and only FDA-approved botulinum toxin stabilized with a proprietary peptide technology, providing long-lasting results for both aesthetic and therapeutic indications. The company also offers the RHA Collection of dermal fillers in the U.S. through a partnership with Teoxane. Revance's portfolio targets significant markets in medical aesthetics and neurology, specifically addressing conditions like glabellar lines and cervical dystonia. In 2024, the company was acquired by Crown Laboratories to create a leading global aesthetics and skincare entity.